Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

psoriatic arthritis alone or with the medicine methotrexate and active ankylosing spondylitis.

"These Phase 3 data show treatment with intravenous golimumab plus methotrexate induced and maintained improvements in the signs and symptoms of rheumatoid arthritis, and inhibited the progression of structural damage.  Such findings are encouraging for rheumatologists and patients," said Rene Westhovens, M.D., Ph.D., Professor at the Department of Rheumatology, KU Leuven, Belgium, and study investigator. "Through week 52, intravenously administered golimumab showed a consistent benefit-to-risk profile compared with previously reported week 24 data."

In the Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNF-alpha Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy (GO-FURTHER), patients were randomized to receive I.V. golimumab 2 mg/kg or placebo, via a 30-minute infusion, plus methotrexate at weeks 0, 4 and then every 8 weeks.  Non-responders to placebo at week 16 were crossed over to receive I.V. golimumab, and all remaining patients receiving placebo crossed over at week 24.  Radiographic progression was assessed by the change from baseline in van der Heijde-Sharp (vdH-S) scores, an X-ray measure of joint destruction, including joint erosion and joint space narrowing in which higher scores indicate greater structural damage.  At week 24, patients receiving I.V. golimumab had a mean change (+/- standard deviation) in total vdH-S score of 0.03 (+/-1.90) from baseline, compared with a mean change of 1.09 (+/- 3.19) in the placebo group (P < 0.001).  At week 52, patients who received the 52-week regimen of I.V. golimumab had a mean change of 0.13 (+/- 3.11) from baseline, compared with a mean change of 1.22 (+/- 3.98) in patients who crossed over fr
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Research ... addition of the "Global and Chinese Hemodialysis ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ...
(Date:10/25/2014)... , Oct. 24, 2014  In 2008, two of ... quantities of multiple controlled substances, on a regular basis, ... reported that Dr. Gurney was practicing "all the time" ... one of his employees said that Dr. Gurney was ... of patients." Dr. Gurney,s behavior became increasingly ...
(Date:10/25/2014)... 24, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Monday, November 3, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... GLEN ALLEN, Va., Feb. 9, 2011 Rock Creek ... CIGX ) announced that on February 4 a ... Trademark Office ("PTO") for administering a pure form of ... be administered in a composition containing a therapeutically effective ...
... 2011 Cyberonics, Inc. (Nasdaq: CYBX ) today ... third quarter ended January 28, 2011 of its fiscal year ... regular market trading hours.  The company will conduct a conference ... 7:30 AM Central Time (8:30 AM Eastern Time). ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 2Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 3Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 4Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011 2
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... getting the right amount of sleep might raise your ... Those who sleep less or more than the recommended ... prone to developing the chronic condition, which causes inflammation ... that duration and quality of sleep are key factors ... "Both short and long durations of sleep have ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... Eric ... web seminar hosted by The Center for Business Intelligence. Tools and real-world examples ... improve the effectiveness and efficiency of their own marketing programs. , ... Waltham, MA (PRWEB) October 28, ...
... the needs of patients and their families has several ... helping to stem the increasing costs of medical errors ... are turning to implementation of patient- and family-centered care ... , The Institute for Family-Centered Care defines PFCC ...
... Michael Feiz , lead surgeon at the Beverly Hills Comprehensive Weight ... than any other doctor. For overweight Los Angeles residents, ... been looking for to shed the unhealthy weight and return to ... Lap Band surgery has the added benefit of enabling the ...
... , WASHINGTON, Oct. 27 The St. Louis Cardinals, new ... as hitting coach sends a message to all baseball and ... CONGRESS INVESTIGATES ," former White House drug policy spokesman Bob ... batters? Grab the drugs? When McGwire used Andro (Androstenedione), now ...
... at the Obesity Society 27th Annual Meeting, shows that ... not as hungry when they were taught how to ... satiating snack of peanuts or peanut butter. These changes ... This study group, which received nutrition education, a snack ...
... methods in a few years , TUESDAY, Oct. 27 (HealthDay ... are equally reliable in screening for cervical cancer, a new ... testing has all but replaced the traditional Pap test, but ... according to Dr. Mark Schiffman, a senior investigator at the ...
Cached Medicine News:Health News:5 Steps to Pharmaceutical Marketing Happiness 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 3Health News:Beverly Hills Doctor (drfeiz.com) Performs the World's Most Lap Band Surgeries 2Health News:Mark McGwire's Message: Cheat, Do Drugs, Cover Up When Congress Investigates, Says Ex-White House Drug Spokesman Bob Weiner; World Series Should Test Both Teams During Games 2Health News:High Nutrient Peanut Snacks Help Overweight Kids Eat Less 2Health News:Old, New Pap Methods Equally Good, Dutch Study Finds 2Health News:Old, New Pap Methods Equally Good, Dutch Study Finds 3
... Upper extremity fixator has been designed to ... by allowing independent movement of its clamp ... goals has been to reduce complexity of ... ease of use. The Hoffmann® II Compact™ ...
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
... components for individual indications. XCaliber covers a ... an innovative composite plastic material, XCaliber is ... This means it's easier to handle, easier ... patient. ,Comes pre-assembled, packaged sterile, and ready ...
Medicine Products: